Seroprevalence of SARS-CoV-2 antibodies among healthy blood donors: a systematic review and meta-analysis
Introduction The development of a potent immune response and antibodies against SARS-CoV-2 is important for herd immunity. The serological response may be due to a previous infection or vaccination. Healthy blood donors could represent and provide information on the immune status of the general popu...
Saved in:
| Published in | BMC public health Vol. 24; no. 1; pp. 2925 - 18 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
22.10.2024
BioMed Central Ltd BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1471-2458 1471-2458 |
| DOI | 10.1186/s12889-024-20364-5 |
Cover
| Abstract | Introduction
The development of a potent immune response and antibodies against SARS-CoV-2 is important for herd immunity. The serological response may be due to a previous infection or vaccination. Healthy blood donors could represent and provide information on the immune status of the general population. Therefore, we estimated the global and regional prevalence of SARS-CoV-2 antibodies among healthy blood donors.
Methods
We conducted a systematic search of PubMed, Scopus, and ProQuest from December 2019 to January 2023. After critical appraisal and quality assessment, a qualitative synthesis of the identified relevant articles was performed. The
random-effects
model was used to estimate the
pooled prevalence
of SARS-CoV-2 antibodies.
Funnel plots
and
Egger
’s test were used to assess publication bias. Sensitivity analysis was performed, and heterogeneity was quantified using
I
2
statistics
.
Results
A total of 70 peer-reviewed articles were selected that together included 2,454,192 blood donors. The global estimated
pooled prevalence
of SARS-CoV-2 antibodies among healthy blood donors was 10.3% (95% CI: 4.6 – 18.0%,
n
= 70). The highest seroprevalence was observed in Asia (17.7%), followed by Africa (16.1%). The seroprevalence in studies conducted
before
the introduction of the vaccine was 6.1%, whereas those of studies conducted
after
vaccines were available was 27.6%. High seroprevalence was observed in studies that measured antibodies against the
S protein
of the virus (15.2%), while lower (12.5%) in those that measured antibodies against the
N protein
. A high seroprevalence was observed in studies that only measured IgG antibodies (16.3%), and it was 5.9% in studies that measured total antibodies.
Conclusion
The prevalence of SARS-CoV-2 antibodies among healthy blood donors varies, potentially indicating geographical disparities in transmission and vaccination rates. To enhance community resilience, addressing these differences through inclusive health policies and adaptable public health measures is crucial. |
|---|---|
| AbstractList | The development of a potent immune response and antibodies against SARS-CoV-2 is important for herd immunity. The serological response may be due to a previous infection or vaccination. Healthy blood donors could represent and provide information on the immune status of the general population. Therefore, we estimated the global and regional prevalence of SARS-CoV-2 antibodies among healthy blood donors.INTRODUCTIONThe development of a potent immune response and antibodies against SARS-CoV-2 is important for herd immunity. The serological response may be due to a previous infection or vaccination. Healthy blood donors could represent and provide information on the immune status of the general population. Therefore, we estimated the global and regional prevalence of SARS-CoV-2 antibodies among healthy blood donors.We conducted a systematic search of PubMed, Scopus, and ProQuest from December 2019 to January 2023. After critical appraisal and quality assessment, a qualitative synthesis of the identified relevant articles was performed. The random-effects model was used to estimate the pooled prevalence of SARS-CoV-2 antibodies. Funnel plots and Egger's test were used to assess publication bias. Sensitivity analysis was performed, and heterogeneity was quantified using I2 statistics.METHODSWe conducted a systematic search of PubMed, Scopus, and ProQuest from December 2019 to January 2023. After critical appraisal and quality assessment, a qualitative synthesis of the identified relevant articles was performed. The random-effects model was used to estimate the pooled prevalence of SARS-CoV-2 antibodies. Funnel plots and Egger's test were used to assess publication bias. Sensitivity analysis was performed, and heterogeneity was quantified using I2 statistics.A total of 70 peer-reviewed articles were selected that together included 2,454,192 blood donors. The global estimated pooled prevalence of SARS-CoV-2 antibodies among healthy blood donors was 10.3% (95% CI: 4.6 - 18.0%, n = 70). The highest seroprevalence was observed in Asia (17.7%), followed by Africa (16.1%). The seroprevalence in studies conducted before the introduction of the vaccine was 6.1%, whereas those of studies conducted after vaccines were available was 27.6%. High seroprevalence was observed in studies that measured antibodies against the S protein of the virus (15.2%), while lower (12.5%) in those that measured antibodies against the N protein. A high seroprevalence was observed in studies that only measured IgG antibodies (16.3%), and it was 5.9% in studies that measured total antibodies.RESULTSA total of 70 peer-reviewed articles were selected that together included 2,454,192 blood donors. The global estimated pooled prevalence of SARS-CoV-2 antibodies among healthy blood donors was 10.3% (95% CI: 4.6 - 18.0%, n = 70). The highest seroprevalence was observed in Asia (17.7%), followed by Africa (16.1%). The seroprevalence in studies conducted before the introduction of the vaccine was 6.1%, whereas those of studies conducted after vaccines were available was 27.6%. High seroprevalence was observed in studies that measured antibodies against the S protein of the virus (15.2%), while lower (12.5%) in those that measured antibodies against the N protein. A high seroprevalence was observed in studies that only measured IgG antibodies (16.3%), and it was 5.9% in studies that measured total antibodies.The prevalence of SARS-CoV-2 antibodies among healthy blood donors varies, potentially indicating geographical disparities in transmission and vaccination rates. To enhance community resilience, addressing these differences through inclusive health policies and adaptable public health measures is crucial.CONCLUSIONThe prevalence of SARS-CoV-2 antibodies among healthy blood donors varies, potentially indicating geographical disparities in transmission and vaccination rates. To enhance community resilience, addressing these differences through inclusive health policies and adaptable public health measures is crucial. IntroductionThe development of a potent immune response and antibodies against SARS-CoV-2 is important for herd immunity. The serological response may be due to a previous infection or vaccination. Healthy blood donors could represent and provide information on the immune status of the general population. Therefore, we estimated the global and regional prevalence of SARS-CoV-2 antibodies among healthy blood donors.MethodsWe conducted a systematic search of PubMed, Scopus, and ProQuest from December 2019 to January 2023. After critical appraisal and quality assessment, a qualitative synthesis of the identified relevant articles was performed. The random-effects model was used to estimate the pooled prevalence of SARS-CoV-2 antibodies. Funnel plots and Egger’s test were used to assess publication bias. Sensitivity analysis was performed, and heterogeneity was quantified using I2statistics.ResultsA total of 70 peer-reviewed articles were selected that together included 2,454,192 blood donors. The global estimated pooled prevalence of SARS-CoV-2 antibodies among healthy blood donors was 10.3% (95% CI: 4.6 – 18.0%, n = 70). The highest seroprevalence was observed in Asia (17.7%), followed by Africa (16.1%). The seroprevalence in studies conducted before the introduction of the vaccine was 6.1%, whereas those of studies conducted after vaccines were available was 27.6%. High seroprevalence was observed in studies that measured antibodies against the S protein of the virus (15.2%), while lower (12.5%) in those that measured antibodies against the N protein. A high seroprevalence was observed in studies that only measured IgG antibodies (16.3%), and it was 5.9% in studies that measured total antibodies.ConclusionThe prevalence of SARS-CoV-2 antibodies among healthy blood donors varies, potentially indicating geographical disparities in transmission and vaccination rates. To enhance community resilience, addressing these differences through inclusive health policies and adaptable public health measures is crucial. The development of a potent immune response and antibodies against SARS-CoV-2 is important for herd immunity. The serological response may be due to a previous infection or vaccination. Healthy blood donors could represent and provide information on the immune status of the general population. Therefore, we estimated the global and regional prevalence of SARS-CoV-2 antibodies among healthy blood donors. We conducted a systematic search of PubMed, Scopus, and ProQuest from December 2019 to January 2023. After critical appraisal and quality assessment, a qualitative synthesis of the identified relevant articles was performed. The random-effects model was used to estimate the pooled prevalence of SARS-CoV-2 antibodies. Funnel plots and Egger's test were used to assess publication bias. Sensitivity analysis was performed, and heterogeneity was quantified using I.sup.2 statistics. A total of 70 peer-reviewed articles were selected that together included 2,454,192 blood donors. The global estimated pooled prevalence of SARS-CoV-2 antibodies among healthy blood donors was 10.3% (95% CI: 4.6 - 18.0%, n = 70). The highest seroprevalence was observed in Asia (17.7%), followed by Africa (16.1%). The seroprevalence in studies conducted before the introduction of the vaccine was 6.1%, whereas those of studies conducted after vaccines were available was 27.6%. High seroprevalence was observed in studies that measured antibodies against the S protein of the virus (15.2%), while lower (12.5%) in those that measured antibodies against the N protein. A high seroprevalence was observed in studies that only measured IgG antibodies (16.3%), and it was 5.9% in studies that measured total antibodies. The prevalence of SARS-CoV-2 antibodies among healthy blood donors varies, potentially indicating geographical disparities in transmission and vaccination rates. To enhance community resilience, addressing these differences through inclusive health policies and adaptable public health measures is crucial. Abstract Introduction The development of a potent immune response and antibodies against SARS-CoV-2 is important for herd immunity. The serological response may be due to a previous infection or vaccination. Healthy blood donors could represent and provide information on the immune status of the general population. Therefore, we estimated the global and regional prevalence of SARS-CoV-2 antibodies among healthy blood donors. Methods We conducted a systematic search of PubMed, Scopus, and ProQuest from December 2019 to January 2023. After critical appraisal and quality assessment, a qualitative synthesis of the identified relevant articles was performed. The random-effects model was used to estimate the pooled prevalence of SARS-CoV-2 antibodies. Funnel plots and Egger’s test were used to assess publication bias. Sensitivity analysis was performed, and heterogeneity was quantified using I 2 statistics. Results A total of 70 peer-reviewed articles were selected that together included 2,454,192 blood donors. The global estimated pooled prevalence of SARS-CoV-2 antibodies among healthy blood donors was 10.3% (95% CI: 4.6 – 18.0%, n = 70). The highest seroprevalence was observed in Asia (17.7%), followed by Africa (16.1%). The seroprevalence in studies conducted before the introduction of the vaccine was 6.1%, whereas those of studies conducted after vaccines were available was 27.6%. High seroprevalence was observed in studies that measured antibodies against the S protein of the virus (15.2%), while lower (12.5%) in those that measured antibodies against the N protein. A high seroprevalence was observed in studies that only measured IgG antibodies (16.3%), and it was 5.9% in studies that measured total antibodies. Conclusion The prevalence of SARS-CoV-2 antibodies among healthy blood donors varies, potentially indicating geographical disparities in transmission and vaccination rates. To enhance community resilience, addressing these differences through inclusive health policies and adaptable public health measures is crucial. Introduction The development of a potent immune response and antibodies against SARS-CoV-2 is important for herd immunity. The serological response may be due to a previous infection or vaccination. Healthy blood donors could represent and provide information on the immune status of the general population. Therefore, we estimated the global and regional prevalence of SARS-CoV-2 antibodies among healthy blood donors. Methods We conducted a systematic search of PubMed, Scopus, and ProQuest from December 2019 to January 2023. After critical appraisal and quality assessment, a qualitative synthesis of the identified relevant articles was performed. The random-effects model was used to estimate the pooled prevalence of SARS-CoV-2 antibodies. Funnel plots and Egger's test were used to assess publication bias. Sensitivity analysis was performed, and heterogeneity was quantified using I.sup.2 statistics. Results A total of 70 peer-reviewed articles were selected that together included 2,454,192 blood donors. The global estimated pooled prevalence of SARS-CoV-2 antibodies among healthy blood donors was 10.3% (95% CI: 4.6 - 18.0%, n = 70). The highest seroprevalence was observed in Asia (17.7%), followed by Africa (16.1%). The seroprevalence in studies conducted before the introduction of the vaccine was 6.1%, whereas those of studies conducted after vaccines were available was 27.6%. High seroprevalence was observed in studies that measured antibodies against the S protein of the virus (15.2%), while lower (12.5%) in those that measured antibodies against the N protein. A high seroprevalence was observed in studies that only measured IgG antibodies (16.3%), and it was 5.9% in studies that measured total antibodies. Conclusion The prevalence of SARS-CoV-2 antibodies among healthy blood donors varies, potentially indicating geographical disparities in transmission and vaccination rates. To enhance community resilience, addressing these differences through inclusive health policies and adaptable public health measures is crucial. Keywords: COVID-19, SARS-CoV-2, Seroprevalence, Blood donors, Antibody The development of a potent immune response and antibodies against SARS-CoV-2 is important for herd immunity. The serological response may be due to a previous infection or vaccination. Healthy blood donors could represent and provide information on the immune status of the general population. Therefore, we estimated the global and regional prevalence of SARS-CoV-2 antibodies among healthy blood donors. We conducted a systematic search of PubMed, Scopus, and ProQuest from December 2019 to January 2023. After critical appraisal and quality assessment, a qualitative synthesis of the identified relevant articles was performed. The random-effects model was used to estimate the pooled prevalence of SARS-CoV-2 antibodies. Funnel plots and Egger's test were used to assess publication bias. Sensitivity analysis was performed, and heterogeneity was quantified using I statistics. A total of 70 peer-reviewed articles were selected that together included 2,454,192 blood donors. The global estimated pooled prevalence of SARS-CoV-2 antibodies among healthy blood donors was 10.3% (95% CI: 4.6 - 18.0%, n = 70). The highest seroprevalence was observed in Asia (17.7%), followed by Africa (16.1%). The seroprevalence in studies conducted before the introduction of the vaccine was 6.1%, whereas those of studies conducted after vaccines were available was 27.6%. High seroprevalence was observed in studies that measured antibodies against the S protein of the virus (15.2%), while lower (12.5%) in those that measured antibodies against the N protein. A high seroprevalence was observed in studies that only measured IgG antibodies (16.3%), and it was 5.9% in studies that measured total antibodies. The prevalence of SARS-CoV-2 antibodies among healthy blood donors varies, potentially indicating geographical disparities in transmission and vaccination rates. To enhance community resilience, addressing these differences through inclusive health policies and adaptable public health measures is crucial. Introduction The development of a potent immune response and antibodies against SARS-CoV-2 is important for herd immunity. The serological response may be due to a previous infection or vaccination. Healthy blood donors could represent and provide information on the immune status of the general population. Therefore, we estimated the global and regional prevalence of SARS-CoV-2 antibodies among healthy blood donors. Methods We conducted a systematic search of PubMed, Scopus, and ProQuest from December 2019 to January 2023. After critical appraisal and quality assessment, a qualitative synthesis of the identified relevant articles was performed. The random-effects model was used to estimate the pooled prevalence of SARS-CoV-2 antibodies. Funnel plots and Egger ’s test were used to assess publication bias. Sensitivity analysis was performed, and heterogeneity was quantified using I 2 statistics . Results A total of 70 peer-reviewed articles were selected that together included 2,454,192 blood donors. The global estimated pooled prevalence of SARS-CoV-2 antibodies among healthy blood donors was 10.3% (95% CI: 4.6 – 18.0%, n = 70). The highest seroprevalence was observed in Asia (17.7%), followed by Africa (16.1%). The seroprevalence in studies conducted before the introduction of the vaccine was 6.1%, whereas those of studies conducted after vaccines were available was 27.6%. High seroprevalence was observed in studies that measured antibodies against the S protein of the virus (15.2%), while lower (12.5%) in those that measured antibodies against the N protein . A high seroprevalence was observed in studies that only measured IgG antibodies (16.3%), and it was 5.9% in studies that measured total antibodies. Conclusion The prevalence of SARS-CoV-2 antibodies among healthy blood donors varies, potentially indicating geographical disparities in transmission and vaccination rates. To enhance community resilience, addressing these differences through inclusive health policies and adaptable public health measures is crucial. |
| ArticleNumber | 2925 |
| Audience | Academic |
| Author | Ukwishaka, Joyeuse Ilboudo, Dieudonné Samadoulougou, Sekou Mela, Cyril Fotabong Ettaj, Malak Danwang, Celestin Kirakoya-Samadoulougou, Fati Aseneh, Jerry Brown Njoh |
| Author_xml | – sequence: 1 givenname: Joyeuse surname: Ukwishaka fullname: Ukwishaka, Joyeuse email: joyukwishaka@gmail.com organization: Rwanda Biomedical Center, Maternal Child and Community Health Division, Jhpiego, Centre de Recherche en Epidémiologie, Biostatistique et Recherche Clinique, Ecole de Santé Publique, Université Libre de Bruxelles – sequence: 2 givenname: Cyril Fotabong surname: Mela fullname: Mela, Cyril Fotabong organization: Centre de Recherche en Epidémiologie, Biostatistique et Recherche Clinique, Ecole de Santé Publique, Université Libre de Bruxelles – sequence: 3 givenname: Jerry Brown Njoh surname: Aseneh fullname: Aseneh, Jerry Brown Njoh organization: Centre de Recherche en Epidémiologie, Biostatistique et Recherche Clinique, Ecole de Santé Publique, Université Libre de Bruxelles – sequence: 4 givenname: Malak surname: Ettaj fullname: Ettaj, Malak organization: Centre de Recherche en Epidémiologie, Biostatistique et Recherche Clinique, Ecole de Santé Publique, Université Libre de Bruxelles, Department of Anthropology, University of California-Davis – sequence: 5 givenname: Dieudonné surname: Ilboudo fullname: Ilboudo, Dieudonné organization: Centre de Recherche en Epidémiologie, Biostatistique et Recherche Clinique, Ecole de Santé Publique, Université Libre de Bruxelles – sequence: 6 givenname: Celestin surname: Danwang fullname: Danwang, Celestin organization: Clinton Health Access Initiative, Inc – sequence: 7 givenname: Sekou surname: Samadoulougou fullname: Samadoulougou, Sekou organization: Evaluation Platform on Obesity Prevention, Quebec Heart and Lung Institute, Centre for Research on Planning and Development, Université Laval – sequence: 8 givenname: Fati surname: Kirakoya-Samadoulougou fullname: Kirakoya-Samadoulougou, Fati organization: Centre de Recherche en Epidémiologie, Biostatistique et Recherche Clinique, Ecole de Santé Publique, Université Libre de Bruxelles |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39438911$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kl1v0zAUhiM0xLbCH-ACReKGmwx_1jE3qKr4mDQJiU7cWifOSesqsYudbuq_x11HWRFCuXDiPOfJOc57WZz54LEoXlNyRWk9fZ8oq2tdESYqRvhUVPJZcUGFohUTsj57cn9eXKa0JoSqWrIXxTnXgtea0ovCLTCGTcQ76NFbLENXLmbfF9U8_KhYCX50TWgdphKG4JflCqEfV7uy6UNoyzb4ENOHEsq0SyMOMDpbZpfD-1zalgOOUIGHfpdcelk876BP-OpxnRS3nz_dzr9WN9--XM9nN5WVUo8VR2Yt6RouOimJaoC3SnGtBCKCJsJOVde0wIBAxxShUINS065pVH4WnE-K64O2DbA2m-gGiDsTwJmHjRCXBmLus0fDVWtBCcJr2wqls6DjSGreaM20VTS7Ph5cm20zYGvRjxH6E-npG-9WZhnuDKWSSkX23bx7NMTwc4tpNINLFvsePIZtMpxSrZikufNJ8fYvdB22MR_enmJTQaXIxiO1zD_MON-F_GG7l5pZTTknesplpq7-QeWrxcHZnKLO5f2TgjdPJz2O-DsoGWAHwMaQUsTuiFBi9mk0hzSanEbzkEazt_JDUcqwX2L8M9J_qn4BooTgkQ |
| Cites_doi | 10.1136/bmjgh-2022-008793 10.1016/S0140-6736(20)30183-5 10.1186/s12879-022-07361-y 10.1002/jmv.25884 10.1056/NEJMoa2115624 10.1056/NEJMp2000929 10.1177/0309133320946302 10.1155/2022/9342680 10.1371/journal.pone.0252617 10.1016/j.ijid.2020.10.104 10.3390/vaccines10122000 10.1038/s41591-022-01739-w 10.1007/s00266-022-02977-6 10.1016/j.ijid.2021.07.027 10.1001/jamanetworkopen.2021.37257 10.1186/s12985-022-01752-y 10.1038/s41467-021-26452-z 10.1093/infdis/jiaa273 10.1186/s40001-022-00710-2 10.1016/j.jhin.2020.11.008 10.1186/s12889-023-15626-7 10.1016/S0140-6736(21)00527-4 10.1056/NEJMoa2114228 10.1016/j.cell.2020.05.015 10.1056/NEJMoa2035389 10.1016/j.diagmicrobio.2020.115140 10.1371/journal.pone.0276829 10.1038/s41598-020-77125-8 10.1111/tmi.13569 10.3390/diagnostics11040678 10.1056/NEJMoa2118946 10.2427/5768 10.1056/NEJMoa2114255 10.1056/NEJMoa2001017 10.1056/NEJMoa2114114 10.1155/2021/2404170 10.1371/journal.pmed.1004107 10.1056/NEJMc2110300 10.1016/S0140-6736(20)31304-0 10.1056/NEJMoa2002032 10.1016/j.arbres.2021.08.019 10.1016/j.envres.2022.112911 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2024 2024. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. 2024. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2024 2024 |
| Copyright_xml | – notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. – notice: 2024. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2024 2024 |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7T2 7TQ 7X7 7XB 88E 8C1 8FE 8FG 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA AN0 ATCPS AZQEC BENPR BGLVJ BHPHI C1K CCPQU COVID DHY DON DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. L6V M0S M1P M7S PATMY PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY 7X8 5PM DOA |
| DOI | 10.1186/s12889-024-20364-5 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health and Safety Science Abstracts (Full archive) PAIS Index Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Public Health Database (ProQuest) ProQuest SciTech Collection ProQuest Technology Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central ProQuest One Sustainability ProQuest Central UK/Ireland British Nursing Database Agricultural & Environmental Science Collection ProQuest Central Essentials ProQuest Central ProQuest Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College Coronavirus Research Database PAIS International PAIS International (Ovid) ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Engineering Collection Health & Medical Collection (Alumni) Medical Database ProQuest Engineering Database Environmental Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student Technology Collection ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection ProQuest Engineering Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Agricultural & Environmental Science Collection Health & Safety Science Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Engineering Database ProQuest Public Health ProQuest One Academic Eastern Edition British Nursing Index with Full Text Coronavirus Research Database ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Environmental Science Collection ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition PAIS International Materials Science & Engineering Collection Environmental Science Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database MEDLINE |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1471-2458 |
| EndPage | 18 |
| ExternalDocumentID | oai_doaj_org_article_37dca74038cd4797aff3e083b9929c71 PMC11515703 A813309635 39438911 10_1186_s12889_024_20364_5 |
| Genre | Meta-Analysis Systematic Review Journal Article |
| GeographicLocations | United States |
| GeographicLocations_xml | – name: United States |
| GroupedDBID | --- 0R~ 23N 2WC 2XV 44B 53G 5VS 6J9 6PF 7X7 7XC 88E 8C1 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAJSJ AASML AAWTL ABDBF ABJCF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADUKV AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AN0 AOIJS ATCPS BAPOH BAWUL BCNDV BENPR BFQNJ BGLVJ BHPHI BMC BNQBC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESTFP ESX F5P FYUFA GROUPED_DOAJ GX1 HCIFZ HMCUK HYE IAO IHR INH INR ITC KQ8 L6V M1P M48 M7S M~E O5R O5S OK1 OVT P2P PATMY PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PTHSS PUEGO PYCSY RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB AAYXX ALIPV CITATION -A0 3V. ACRMQ ADINQ C24 CGR CUY CVF ECM EIF NPM PMFND 7T2 7TQ 7XB 8FK AZQEC C1K COVID DHY DON DWQXO GNUQQ K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c559t-3e2cc0fb34f5507ba3d773974eeea904c67fbda2a0af2701a8a776fbb7af2433 |
| IEDL.DBID | M48 |
| ISSN | 1471-2458 |
| IngestDate | Wed Aug 27 01:09:42 EDT 2025 Thu Aug 21 18:44:09 EDT 2025 Sat Sep 27 21:12:12 EDT 2025 Fri Jul 25 19:04:47 EDT 2025 Tue Jun 17 22:03:03 EDT 2025 Tue Jun 10 21:03:40 EDT 2025 Fri Feb 07 01:37:44 EST 2025 Tue Jul 01 02:14:10 EDT 2025 Sat Sep 06 07:29:09 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | COVID-19 SARS-CoV-2 Antibody Blood donors Seroprevalence |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c559t-3e2cc0fb34f5507ba3d773974eeea904c67fbda2a0af2701a8a776fbb7af2433 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://www.proquest.com/docview/3126415470?pq-origsite=%requestingapplication%&accountid=15518 |
| PMID | 39438911 |
| PQID | 3126415470 |
| PQPubID | 44782 |
| PageCount | 18 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_37dca74038cd4797aff3e083b9929c71 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11515703 proquest_miscellaneous_3119725124 proquest_journals_3126415470 gale_infotracmisc_A813309635 gale_infotracacademiconefile_A813309635 pubmed_primary_39438911 crossref_primary_10_1186_s12889_024_20364_5 springer_journals_10_1186_s12889_024_20364_5 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-10-22 |
| PublicationDateYYYYMMDD | 2024-10-22 |
| PublicationDate_xml | – month: 10 year: 2024 text: 2024-10-22 day: 22 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC public health |
| PublicationTitleAbbrev | BMC Public Health |
| PublicationTitleAlternate | BMC Public Health |
| PublicationYear | 2024 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | N Zhu (20364_CR1) 2020; 382 C Huang (20364_CR2) 2020; 395 D Kundu (20364_CR49) 2022; 22 M Lisboa Bastos (20364_CR51) 2020; 1 L Chu (20364_CR15) 2022; 28 20364_CR39 F Wolff (20364_CR20) 2020; 98 S Pilz (20364_CR38) 2022; 209 20364_CR46 P Emmerich (20364_CR53) 2021; 26 CDC (20364_CR16) 2022 J Zhu (20364_CR5) 2020; 92 H Chemaitelly (20364_CR40) 2021; 385 R Arbel (20364_CR43) 2021; 385 WHO (20364_CR3) 2020 YM Bar-On (20364_CR44) 2021; 385 K Guevara-Hoyer (20364_CR18) 2021; 11 PD Burbelo (20364_CR19) 2020; 222 LR Baden (20364_CR41) 2021; 384 20364_CR27 20364_CR37 20364_CR36 20364_CR35 Y Chen (20364_CR28) 2023; 47 20364_CR32 S Stringhini (20364_CR24) 2020; 396 20364_CR31 T Chandra (20364_CR25) 2021; 29 20364_CR6 JB Soriano (20364_CR9) 2022; 58 HC Lewis (20364_CR30) 2022; 7 T Perkmann (20364_CR47) 2023; 1 WJ Guan (20364_CR4) 2020; 382 WHO (20364_CR7) 2023 WHO (20364_CR12) 2023 20364_CR26 VJ Munster (20364_CR23) 2020; 382 FY Tso (20364_CR52) 2021; 1 M Azami (20364_CR29) 2022; 27 R Naeimi (20364_CR33) 2023; 1 WHO (20364_CR22) 2022 GP Milani (20364_CR14) 2020; 10 X Ma (20364_CR50) 2022; 10 A Celikgil (20364_CR17) 2023; 18 Y Goldberg (20364_CR42) 2021; 385 WHO (20364_CR10) 2021 Y Goldberg (20364_CR45) 2022; 386 A Grifoni (20364_CR13) 2020; 181 WHO (20364_CR8) 2020 M Yamamoto (20364_CR56) 2022; 19 WHO (20364_CR21) 2020 E Brochot (20364_CR48) 2020; 1 20364_CR11 N Irwin (20364_CR54) 2021; 1 C Bottomley (20364_CR55) 2021; 12 P Galanis (20364_CR34) 2021; 108 |
| References_xml | – volume: 7 start-page: e008793 year: 2022 ident: 20364_CR30 publication-title: BMJ Glob Health doi: 10.1136/bmjgh-2022-008793 – volume: 1 start-page: 158 year: 2023 ident: 20364_CR47 publication-title: J Clin Virol – volume: 1 start-page: 370 year: 2020 ident: 20364_CR51 publication-title: BMJ – volume-title: Vaccine efficacy, effectiveness and protection year: 2021 ident: 20364_CR10 – volume-title: Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic year: 2023 ident: 20364_CR12 – volume: 395 start-page: 497 issue: 10223 year: 2020 ident: 20364_CR2 publication-title: Lancet doi: 10.1016/S0140-6736(20)30183-5 – volume-title: Coronavirus disease (COVID-19): herd immunity, lockdowns and COVID-19 year: 2020 ident: 20364_CR21 – ident: 20364_CR11 – volume: 22 start-page: 390 issue: 1 year: 2022 ident: 20364_CR49 publication-title: BMC Infect Dis doi: 10.1186/s12879-022-07361-y – volume: 92 start-page: 1902 issue: 10 year: 2020 ident: 20364_CR5 publication-title: J Med Virol doi: 10.1002/jmv.25884 – volume: 385 start-page: 2413 issue: 26 year: 2021 ident: 20364_CR43 publication-title: N Engl J Med doi: 10.1056/NEJMoa2115624 – volume: 382 start-page: 692 issue: 8 year: 2020 ident: 20364_CR23 publication-title: N Engl J Med doi: 10.1056/NEJMp2000929 – ident: 20364_CR36 doi: 10.1177/0309133320946302 – ident: 20364_CR35 doi: 10.1155/2022/9342680 – ident: 20364_CR32 doi: 10.1371/journal.pone.0252617 – volume: 1 start-page: 577 issue: 102 year: 2021 ident: 20364_CR52 publication-title: Int J Infect Dis doi: 10.1016/j.ijid.2020.10.104 – volume: 10 start-page: 2000 issue: 12 year: 2022 ident: 20364_CR50 publication-title: Vaccines (Basel) doi: 10.3390/vaccines10122000 – volume: 28 start-page: 1042 issue: 5 year: 2022 ident: 20364_CR15 publication-title: Nat Med doi: 10.1038/s41591-022-01739-w – volume: 1 start-page: 130 year: 2020 ident: 20364_CR48 publication-title: J Clin Virol – volume-title: Public health surveillance for COVID-19: interim guidance year: 2022 ident: 20364_CR22 – volume: 47 start-page: 83 year: 2023 ident: 20364_CR28 publication-title: Aesthetic Plast Surg doi: 10.1007/s00266-022-02977-6 – volume-title: Coronavirus disease (COVID-19) pandemic year: 2023 ident: 20364_CR7 – volume: 1 start-page: 304 issue: 109 year: 2021 ident: 20364_CR54 publication-title: Int J Infect Dis doi: 10.1016/j.ijid.2021.07.027 – ident: 20364_CR6 doi: 10.1001/jamanetworkopen.2021.37257 – ident: 20364_CR27 – volume: 19 start-page: 24 issue: 1 year: 2022 ident: 20364_CR56 publication-title: Virol J doi: 10.1186/s12985-022-01752-y – volume-title: Interim guidelines for COVID-19 antibody testing year: 2022 ident: 20364_CR16 – volume: 12 start-page: 6196 issue: 1 year: 2021 ident: 20364_CR55 publication-title: Nat Commun doi: 10.1038/s41467-021-26452-z – volume: 222 start-page: 206 year: 2020 ident: 20364_CR19 publication-title: J Infect Dis doi: 10.1093/infdis/jiaa273 – volume: 27 start-page: 81 year: 2022 ident: 20364_CR29 publication-title: Eur J Med Res doi: 10.1186/s40001-022-00710-2 – volume: 108 start-page: 120 year: 2021 ident: 20364_CR34 publication-title: J Hosp Infect doi: 10.1016/j.jhin.2020.11.008 – ident: 20364_CR37 doi: 10.1186/s12889-023-15626-7 – ident: 20364_CR46 doi: 10.1016/S0140-6736(21)00527-4 – volume-title: WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020 year: 2020 ident: 20364_CR3 – volume: 385 start-page: e85 issue: 24 year: 2021 ident: 20364_CR42 publication-title: N Engl J Med doi: 10.1056/NEJMoa2114228 – volume: 181 start-page: 1489 issue: 7 year: 2020 ident: 20364_CR13 publication-title: Cell doi: 10.1016/j.cell.2020.05.015 – volume: 384 start-page: 403 issue: 5 year: 2021 ident: 20364_CR41 publication-title: N Engl J Med doi: 10.1056/NEJMoa2035389 – volume: 98 start-page: 115140 issue: 3 year: 2020 ident: 20364_CR20 publication-title: Diagn Microbiol Infect Dis. doi: 10.1016/j.diagmicrobio.2020.115140 – volume: 18 start-page: e0276829 issue: 2 February year: 2023 ident: 20364_CR17 publication-title: PLoS One doi: 10.1371/journal.pone.0276829 – volume: 1 start-page: 56 year: 2023 ident: 20364_CR33 publication-title: EClinicalMedicine – volume: 10 start-page: 20048 issue: 1 year: 2020 ident: 20364_CR14 publication-title: Sci Rep doi: 10.1038/s41598-020-77125-8 – volume: 26 start-page: 621 issue: 6 year: 2021 ident: 20364_CR53 publication-title: Trop Med Int Health doi: 10.1111/tmi.13569 – volume: 11 start-page: 678 issue: 4 year: 2021 ident: 20364_CR18 publication-title: Diagnostics doi: 10.3390/diagnostics11040678 – volume-title: Listings of WHO’s response to COVID-19 year: 2020 ident: 20364_CR8 – volume: 386 start-page: 2201 issue: 23 year: 2022 ident: 20364_CR45 publication-title: N Engl J Med doi: 10.1056/NEJMoa2118946 – ident: 20364_CR26 doi: 10.2427/5768 – volume: 385 start-page: 1393 issue: 15 year: 2021 ident: 20364_CR44 publication-title: N Engl J Med doi: 10.1056/NEJMoa2114255 – volume: 382 start-page: 727 issue: 8 year: 2020 ident: 20364_CR1 publication-title: N Engl J Med doi: 10.1056/NEJMoa2001017 – ident: 20364_CR39 doi: 10.1056/NEJMoa2114114 – volume: 29 start-page: 1 issue: 2021 year: 2021 ident: 20364_CR25 publication-title: Adv Med doi: 10.1155/2021/2404170 – ident: 20364_CR31 doi: 10.1371/journal.pmed.1004107 – volume: 385 start-page: 2582 issue: 27 year: 2021 ident: 20364_CR40 publication-title: N Engl J Med doi: 10.1056/NEJMc2110300 – volume: 396 start-page: 313 issue: 10247 year: 2020 ident: 20364_CR24 publication-title: Lancet doi: 10.1016/S0140-6736(20)31304-0 – volume: 382 start-page: 1708 issue: 18 year: 2020 ident: 20364_CR4 publication-title: N Engl J Med doi: 10.1056/NEJMoa2002032 – volume: 58 start-page: 213 year: 2022 ident: 20364_CR9 publication-title: Arch Bronconeumol doi: 10.1016/j.arbres.2021.08.019 – volume: 209 start-page: 112911 year: 2022 ident: 20364_CR38 publication-title: Environ Res doi: 10.1016/j.envres.2022.112911 |
| SSID | ssj0017852 |
| Score | 2.428615 |
| SecondaryResourceType | review_article |
| Snippet | Introduction
The development of a potent immune response and antibodies against SARS-CoV-2 is important for herd immunity. The serological response may be due... The development of a potent immune response and antibodies against SARS-CoV-2 is important for herd immunity. The serological response may be due to a previous... Introduction The development of a potent immune response and antibodies against SARS-CoV-2 is important for herd immunity. The serological response may be due... IntroductionThe development of a potent immune response and antibodies against SARS-CoV-2 is important for herd immunity. The serological response may be due... Abstract Introduction The development of a potent immune response and antibodies against SARS-CoV-2 is important for herd immunity. The serological response... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 2925 |
| SubjectTerms | Antibodies Antibodies, Viral - blood Antibody Asymptomatic Biostatistics Blood Blood & organ donations Blood donors Blood Donors - statistics & numerical data COVID-19 COVID-19 - immunology COVID-19 - prevention & control COVID-19 vaccines Disease transmission Environmental Health Epidemiology Evaluation Health aspects Health care Health policy Herd immunity Heterogeneity Humans Immune response Immune status Immune system Immunity (Disease) Immunization Immunoglobulin G Immunoglobulins Infections Medicine Medicine & Public Health Meta-analysis N protein Observational studies Pandemics Proteins Public Health Qualitative analysis Quality assessment Quality control Regional development SARS-CoV-2 SARS-CoV-2 - immunology Sensitivity analysis Seroepidemiologic Studies Serology Seroprevalence Severe acute respiratory syndrome coronavirus 2 Systematic review Vaccine Vaccines Viral antibodies Viral diseases Viruses |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQT0gI8SZQkJGQOIBVx3bihNtSUVVIcKAF9WaNX2IPTVB3e-DfM7aTbVOEuHCNHcWeh2cmnvmGkNc-otmy0bG2V8CUq2sGDjBU6aXrQmtD61OB8-cv7fE39emsObvW6ivlhBV44EK4A6m9A624TF12dK8hRhnQb7A9GnaXq8cF7_kcTE33B7prxFwi07UHGzyFU2qQUCxfvLFmYYYyWv-fZ_I1o3QzYfLGrWk2Rkf3yN3Ji6Srsvr75FYYHpA75RccLZVFD8kaz4HU4wRlKakvHSM9WX09YYfjdyYoUnRtx5RDSHPDIVoqIn_RnMpO_TiMF5v3FOgV1jMtdS74qqfnYQsMJkSTR-T06OPp4TGbOiswhxHElskgnOPRShUTnpkF6bVGz0SFEKDnyrU6Wg8COESheQ0daN1Ga5H8Qkn5mOwN4xCeEtq04COXmoP1yssANffSyj7UorUcQkXeznQ2Pwt-hslxR9eawhWDXDGZK6apyIfEit3MhH2dH6BEmEkizL8koiJvEiNN0lDkloOp0AAXnLCuzKrDuBwjN4mf21_MRM1yy-FZFMyk2RsjcWPo9CjNK_JqN5zeTNlqQxgv05zUzA1dKVWRJ0VydluSfeo3X-Mqu4VMLfa8HBnWPzLud52cTzyhK_JuFr-rdf2dqM_-B1Gfk9siqQ9abSH2yd724jK8QHdsa19mzfsNhO4xPA priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELbK9oKEEOUZKMhISBzAqhM7cVKpQtuqVYXECrUF9Wb5lbIHkrK7PfDvmXGS3aYIjhs7Wtvzjme-IeSdr8Fs2dqxopKGSZemzDgDoUolXBkKGwqPBc5fZsXpN_n5Mr_cIrOhFgbTKgedGBW1bx1-I98TKZhusPeKf7r-xbBrFN6uDi00TN9awR9EiLF7ZBtUcs4nZPvwePb1bH2voMo8G0pnymJvCdoZU4YyyeKFHMtH5imi-P-tq28Zq7uJlHduU6OROnlEHvbeJZ127LBDtkLzmDzoPs3RruLoCZmDfsDeJ8BjKNa0ren59OycHbXfWUbhpOe2xdxCGhsR0a5S8jeNKe7Ut027WO5TQzcY0LSrf4FXPf0ZVoaZHunkKbk4Ob44OmV9xwXmILJYMREy53hthawR58wa4ZUCj0WGEEzFpStUbb3JDDd1pnhqSqNUUVur4LcU4hmZNG0TXhCaF8bXXChurJdeBJNyL6yoApDRchMS8mE4Z33d4WroGI-Uhe6oooEqOlJF5wk5RFKsZyImdnzQLq50L2JaKO-MklxgPyZVwZJqEcDDtBW4gE6lCXmPhNQouUAtZ_oCBFgwYmDpaQnxOkR0Av5udzQTJM6NhwdW0L3EL_WGPxPydj2Mb2IWWxPaG5yDTd7AxZIJed5xznpLosI-9Cmsshzx1GjP45Fm_iPigafolILmTsjHgf026_r3ob78_zZekfsZCgbY6SzbJZPV4ia8BgdsZd_0UvUHpHsvWw priority: 102 providerName: ProQuest – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR1LaxQxOGgFEUS0vkarRBA8aDCTZJIZb3WxFKEebJXeQp50D85Id3vw3_t9mdltp-rB40wSJsn3nu9FyOuYQWz5HJjulGMq1DVzwYGp0snQJu2TjpjgfPRFH35Tn0-b06lMDubCXPXf161-vwL-iUE9QrHiMmPNTXKrAcaL2LzQi63HwLSN2CTF_HXdTPCU-vx_cuErYuh6iOQ1P2kRPwf3yb1Jb6T7I6AfkBup3yW3jybP-C65O_5_o2Na0UOyBCaADU4AkZB26ZDp8f7XY7YYvjNB4TqXfsAAQlq6DdExHfIXLXHsNA79cL76QB29LPRMxyQXWBrpj7R2zE3lTB6Rk4NPJ4tDNrVVYAHMhzWTSYTAs5cqYzEz72Q0BtQSlVJyHVdBm-yjE467LAyvXeuM0dl7A89Kysdkpx_69JTQRruYuTTc-aiiTK7mUXrZpVpoz12qyNvNldufY_EMW4yOVtsRQBYAZAuAbFORjwiV7UwsfF1eAD7YiY6sNDE4o7jEpkumgy1lmUCN9B3oecHUFXmDMLVIngC44KYsA9gwFrqy-y0Y5WC2Sfjc3mwmkFWYD2-wwk5kvbISDgYajzK8Iq-2w7gSQ9X6NFzgHOzkBnqUqsiTEYm2R5IdNpuvYZftDL1mZ56P9MuzUvS7Rs0T2HNF3m0w8XJf_77UZ_83_Tm5I5BmQDgLsUd21ucX6QVoXWv_spDbb91gJQI priority: 102 providerName: Springer Nature |
| Title | Seroprevalence of SARS-CoV-2 antibodies among healthy blood donors: a systematic review and meta-analysis |
| URI | https://link.springer.com/article/10.1186/s12889-024-20364-5 https://www.ncbi.nlm.nih.gov/pubmed/39438911 https://www.proquest.com/docview/3126415470 https://www.proquest.com/docview/3119725124 https://pubmed.ncbi.nlm.nih.gov/PMC11515703 https://doaj.org/article/37dca74038cd4797aff3e083b9929c71 |
| Volume | 24 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjR1ri9QwMNzjiyDi2-q5RBD8oNE2ySatILK73HoIHrJ3K4dfQl7VBW11dw-8f-8kbXfteYJfAm3SNplHZqaZB0JPXQliy5SWiIJrwm2WEW01mCoFs7kXxgsXApw_HIujOX9_NjzbQV25oxaAqytNu1BPar789vLXz4u3wPBvIsPn4tUK9tjg-EM5icdqZLiL9uN5UXDl49tTBZnHCjwZbMiE8mHeBdFc-Y6eoIr5_P_etf8QW5ddKi-dq0ZxNb2JbrR6Jh41hHEL7fjqNrre_KTDTezRHbSAnSJUQQFqCwyO6xKfjGYnZFJ_IhQDzBemDl6GOJYkwk3M5AWOzu7Y1VW9XL3GGm-zQeMmEgYedfi7X2ui25wnd9Hp9PB0ckTa2gvEgo2xJsxTa9PSMF6GjGdGMycl6C7ce6-LlFshS-M01akuqUwznWspRWmMhGvO2D20V9WVf4DwUGhXpkym2jjumNdZ6phhhc-oMKn2CXrewVn9aDJsqGiZ5EI1WFGAFRWxooYJGgdUbEaG7NjxRr38olpmU0w6qyVPWajMJAuYUsk86JqmAGXQyixBzwIiVaAqwJbVbSgCTDhkw1KjHCx3sO0YfO6gNxJ4z_a7O1JQHekqBgsDtYjLNEFPNt3hyeDPVvn6PIwJ5d5A2eIJut9QzmZJrAgV6TOYZd6jqd6a-z3V4mvMDJ4F9RT28AS96MhvO69_A_Xhf8PjEbpGA4-A8Kb0AO2tl-f-MWhlazNAu_JMQptPstBO3w3Q_vjw-OMMriZiMoh_OwaRIaGdjT9DO6ej32zpOgg |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Jb9QwFLaq6QEkhNgJFDASiANYTWInTpAqNC2tprQdoXaoerO8BeZAUmamQv1x_DfeyzJDiuDWY2JHsf2W79l-CyGvXAGwZQrL0lxoJmwUMW01bFVybjOfGp86DHA-GqejL-LTWXK2Rn51sTDoVtnpxFpRu8riGfkmjwC6Ae9l-OH8B8OqUXi72pXQ0G1pBbdVpxhrAzsO_OVP2MLNt_Y_Ar1fx_He7mRnxNoqA8yCNb1g3MfWhoXhosDcXkZzJyWgtPDe6zwUNpWFcTrWoS5iGUY601KmhTESngWehwICrAs8PxmQ9e3d8efj5TWGzJK4i9TJ0s05gAF6KMWC1fd_LOmhYV004G9o-AMbr_ptXrm8rTFx7w653RqzdNhw312y5st75FZzEkibAKf7ZArqCEutAEujFqFVQU-GxydspzplMQXCTk2Froy0rntEm8DMS1p71FNXldVs_p5quko5TZtwG_jU0e9-oZluE6s8IJPrWPqHZFBWpX9MaJJqV4Rchto44bjXUei44bkHrjGh9gF5262zOm_SeKh6-5OlqqGKAqqomioqCcg2kmLZE1Nw1y-q2VfVSrTi0lktRcix_JPMYUgF92DQmhwsTiujgLxBQipUFEAtq9t4BxgwptxSwyziHDaQHH630esJAm77zR0rqFbBzNVKHALyctmMX6LTXOmrC-yDNeXAohMBedRwznJKPMey9xGMMuvxVG_O_ZZy-q1OPx6hDQxAEZB3HfutxvXvRX3y_2m8IDdGk6NDdbg_PnhKbsYoJGAixPEGGSxmF_4Z2H4L87yVMErUNcv0b9a8bRA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdgSBMSQjBgBAYYCYkHsJbYbpzwVgbV-NiE2Ib2ZvkT-kAytdkD_z13TtotAx54bG2rtu_Od9e7-x0hL3wEtWWjY2UtDZOuKJhxBlyVWrgqlDaUHgucDw7L_RP58XRyeqmKP2W7r0KSfU0DojQ13e6Zj72IV-XuEl5VTPXhkqVAGptcJzck6GpM6jrh03UcQVUTviqV-eu6kTpKqP1_vs2XlNPVxMkr0dOklGZ3yO3BmqTTnvx3ybXQbJHNgyFevkVu9f_K0b7Y6B6Zw9OAbU-AvVCiaRvp0fTrEdtrvzFO4ZLntsW0Qpp6ENG-SPIXTdnt1LdNu1i-oYZewD_TvvQFlnr6M3SGmQHk5D45nr0_3ttnQ7MF5sCp6JgI3Lk8WiEjQpxZI7xSYKzIEIKpc-lKFa033OQmcpUXpjJKldFaBZ-lEA_IRtM24SGhk9L4mAuVG-ulF8EUuRdW1KHgpc1NyMir1ZXrsx5SQydXpCp1TyANBNKJQHqSkbdIlfVMhMNOX7SL73qQLi2Ud0bJXGArJlXDlqIIYFzaGqw_p4qMvESaahRaIJwzQ-0BbBjhr_S0AlcdnDkBP7czmgnC5sbDK67Qg7AvtYCDgR0kVZ6R5-thXIkJbE1oz3EO9ncD60pmZLtnovWRRI0t6AvYZTVir9GZxyPN_EeCAi_QHoVHOyOvV5x4sa9_X-qj_5v-jGx-eTfTnz8cfnpMbnIUH9DenO-QjW5xHp6AWdbZp0nyfgNUpzBX |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Seroprevalence+of+SARS-CoV-2+antibodies+among+healthy+blood+donors%3A+a+systematic+review+and+meta-analysis&rft.jtitle=BMC+public+health&rft.au=Ukwishaka%2C+Joyeuse&rft.au=Mela%2C+Cyril+Fotabong&rft.au=Aseneh%2C+Jerry+Brown+Njoh&rft.au=Ettaj%2C+Malak&rft.date=2024-10-22&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2458&rft.eissn=1471-2458&rft.volume=24&rft.issue=1&rft_id=info:doi/10.1186%2Fs12889-024-20364-5&rft.externalDocID=A813309635 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2458&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2458&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2458&client=summon |